ES2155519T3 - Preparaciones inmunoterapeuticas que contienen gamma-globulinas para tratar enfermedades cancerosas. - Google Patents

Preparaciones inmunoterapeuticas que contienen gamma-globulinas para tratar enfermedades cancerosas.

Info

Publication number
ES2155519T3
ES2155519T3 ES95912808T ES95912808T ES2155519T3 ES 2155519 T3 ES2155519 T3 ES 2155519T3 ES 95912808 T ES95912808 T ES 95912808T ES 95912808 T ES95912808 T ES 95912808T ES 2155519 T3 ES2155519 T3 ES 2155519T3
Authority
ES
Spain
Prior art keywords
preparation
diseases
methods
cancerose
globulines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95912808T
Other languages
English (en)
Inventor
Yehuda Shoenfeld
Pnina Fishman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARP Biomed Ltd
Original Assignee
ARP Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26907064&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2155519(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ARP Biomed Ltd filed Critical ARP Biomed Ltd
Application granted granted Critical
Publication of ES2155519T3 publication Critical patent/ES2155519T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION PROPORCIONA METODOS TERAPEUTICOS PARA INHIBIR LA METASTASIS DE TUMORES Y PARA EL TRATAMIENTO DE TUMORES PRIMARIOS. LOS METODOS DE LA PRESENTE INVENCION NO PRODUCEN EFECTOS SECUNDARIOS GRAVES Y SON EFICACES PARA UN AMPLIO ESPECTRO DE ENFERMEDADES CANCEROSAS. EN PARTICULAR, LA INVENCION REVELA UN METODO NUEVO QUE CONSISTE EN LA ADMINISTRACION INTRAVENOSA A UN MAMIFERO DE UN PREPARADO DE INMUNOGLOBULINAS (IVIG). SEGUN LA INVENCION, EL PREPARADO IVIG QUE SE ADMINISTRA PUEDE CONTENER MOLECULAS INTACTAS DE INMUNOGLOBULINA O FRAGMENTOS DE INMUNOGLOBULINAS. EL PREPARADO SE ADMINISTRA POR VIA PARENTERAL, PREFERENTEMENTE POR VIA INTRAVENOSA, INTRACAVITARIA O SUBCUTANEA, YA SEA COMO UN AGENTE UNICO O EN COMBINACION CON OTROS AGENTES O METODOS UTILIZADOS HABITUALMENTE PARA EL TRATAMIENTO CONTRA EL CANCER.
ES95912808T 1994-03-14 1995-03-09 Preparaciones inmunoterapeuticas que contienen gamma-globulinas para tratar enfermedades cancerosas. Expired - Lifetime ES2155519T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21236194A 1994-03-14 1994-03-14
US08/340,094 US5562902A (en) 1994-03-14 1994-11-15 Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin

Publications (1)

Publication Number Publication Date
ES2155519T3 true ES2155519T3 (es) 2001-05-16

Family

ID=26907064

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95912808T Expired - Lifetime ES2155519T3 (es) 1994-03-14 1995-03-09 Preparaciones inmunoterapeuticas que contienen gamma-globulinas para tratar enfermedades cancerosas.

Country Status (20)

Country Link
US (2) US5562902A (es)
EP (1) EP0750514B1 (es)
JP (2) JP4004062B2 (es)
KR (1) KR100352583B1 (es)
CN (1) CN1089007C (es)
AT (1) ATE198711T1 (es)
AU (1) AU700751B2 (es)
BR (1) BR9507067A (es)
CA (1) CA2184269A1 (es)
DE (1) DE69519924T2 (es)
DK (1) DK0750514T3 (es)
ES (1) ES2155519T3 (es)
FI (1) FI114011B (es)
GR (1) GR3035758T3 (es)
HK (1) HK1014493A1 (es)
IL (1) IL112963A (es)
NZ (1) NZ282659A (es)
PT (1) PT750514E (es)
TW (1) TW418091B (es)
WO (1) WO1995024927A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166313A1 (en) * 1994-03-14 2007-07-19 Yehuda Shoenfeld Administration of gamma globulins to treat cancer
US20080050390A1 (en) * 1994-03-14 2008-02-28 Yehuda Shoenfeld Administration of gamma globulins to treat metastatic melanoma
WO1999057152A1 (en) 1998-05-07 1999-11-11 Research Corporation Technologies, Inc. Oral administration of immunoglobulins for treating autoimmune hearing loss
TWI248819B (en) * 1999-09-27 2006-02-11 Arp Biomed Ltd Pharmaceutical composition containing IVIG for use in treating lymphoma
WO2001066124A2 (en) * 2000-03-10 2001-09-13 Medinnova Sf Composition for the treatment of heart failure
AT410637B (de) * 2001-06-01 2003-06-25 Igeneon Krebs Immuntherapie Verwendung von polyklonalen immunglobulinen
US20050106136A1 (en) 2002-02-15 2005-05-19 Richard Brunner 7s immunoglobulin for treatment of choroidal neovascularisation
US20080031903A1 (en) * 2006-07-27 2008-02-07 Andrea Gambotto Method of treating ocular infections
EP2214710A1 (en) * 2007-05-07 2010-08-11 Gammacan Human anti-vegf polyclonal antibodies and uses thereof
WO2010093606A1 (en) * 2009-02-11 2010-08-19 Martin Heath Bluth Reciprocal serum/plasma exchange for the treatment of cancer
CN114129722B (zh) * 2020-09-04 2024-04-05 中国医学科学院输血研究所 注射用人免疫球蛋白在制备预防或治疗辐照损伤的药物中的用途
CN114392351B (zh) * 2021-07-13 2024-04-05 中国医学科学院放射医学研究所 毛螺菌科细菌与注射用人免疫球蛋白的联合用药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699783A (en) * 1983-03-11 1987-10-13 Terman David S Products and methods for treatment of cancer
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
TWI248819B (en) * 1999-09-27 2006-02-11 Arp Biomed Ltd Pharmaceutical composition containing IVIG for use in treating lymphoma

Also Published As

Publication number Publication date
FI963598A0 (fi) 1996-09-12
EP0750514A1 (en) 1997-01-02
IL112963A0 (en) 1995-06-29
US5562902A (en) 1996-10-08
CA2184269A1 (en) 1995-09-21
IL112963A (en) 2000-02-17
TW418091B (en) 2001-01-11
KR100352583B1 (ko) 2002-12-26
PT750514E (pt) 2001-06-29
FI114011B (fi) 2004-07-30
JPH09512791A (ja) 1997-12-22
GR3035758T3 (en) 2001-07-31
DK0750514T3 (da) 2001-05-21
DE69519924D1 (de) 2001-02-22
AU700751B2 (en) 1999-01-14
HK1014493A1 (en) 1999-09-30
JP2007119493A (ja) 2007-05-17
ATE198711T1 (de) 2001-02-15
BR9507067A (pt) 1997-09-30
FI963598A (fi) 1996-09-12
CN1089007C (zh) 2002-08-14
NZ282659A (en) 1998-06-26
JP4004062B2 (ja) 2007-11-07
AU1984895A (en) 1995-10-03
CN1148343A (zh) 1997-04-23
US5965130A (en) 1999-10-12
WO1995024927A1 (en) 1995-09-21
EP0750514B1 (en) 2001-01-17
DE69519924T2 (de) 2001-08-23

Similar Documents

Publication Publication Date Title
MY112405A (en) Method of tumer treatment.
GR3032511T3 (en) Combination with anti-hormonal compounds and binding molecules for the treatment of cancer.
ES2155519T3 (es) Preparaciones inmunoterapeuticas que contienen gamma-globulinas para tratar enfermedades cancerosas.
YU13603A (sh) Postupci tretiranja poremećaja povenzanih sa bcl-2 primenom bcl-2 antisens oligomera
EP0719150A4 (en) CELL VACCINE AND METHODS OF USE IN THE TREATMENT OF SOLID MALIGNANT TUMORS
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
ES2123642T3 (es) Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.
PT944389E (pt) Composições purificadas de 10-propargil-10-desaza-aminopterina e métodos para a sua utilização no tratamento de tumores
GB8805792D0 (en) Medicaments
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
BR9808263A (pt) Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto.
DE60116075D1 (de) Behandlung von tumoren mit photodynamischer therapie
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
HK1049608A1 (zh) 丙種球蛋白的投藥治療淋巴瘤
BR0211436A (pt) Método e composição para tratamento de câncer
RU2093219C1 (ru) Способ лечения рака пищевода
DE59009724D1 (de) Verwendung von 7-oh-1,2-benzopyron zur herstellung eines arzneimittels zur behandlung von malignen tumoren beim menschen.
DE59506911D1 (de) Verwendung von intravenös applizierbarem eisen zur therapie von tumorerkrankungen und/oder infektionskrankheiten
RU97114158A (ru) Способ лечения злокачественных опухолей

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 750514

Country of ref document: ES